Abstracts tagged "interleukins (IL) and systemic lupus erythematosus (SLE)"

Abstract Number: 1086 • 2018 ACR/ARHP Annual Meeting
Low-Dose IL-2 Combined with Rapamycin Efficiently Promotes Remission of Refractory Systemic Lupus Erythematosus
Zhaoyun Liang¹, Xiaona Jing¹, Meihua Hao¹, Chong Gao², Xiao-Feng Li³ and Junwei Chen¹, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, ³Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose: Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease. Regulatory T (Treg) cells and T helper type 17 (Th17) cells play opposite roles…
Abstract Number: 2785 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 1-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study
Ronald van Vollenhoven¹, Bevra H Hahn², George C Tsokos³, Carrie Wagner⁴, Peter Lipsky⁵, Benjamin Hsu⁴, Marc Chevrier⁴, Robert Gordon⁴, Kim Hung Lo⁴, Manon Triebel⁶, Kaiyin Fei⁴ and Shawn Rose⁴, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²University of California, Los Angeles, CA, ³Beth Israel Hospital, Boston, MA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA, ⁶Janssen Biologics Europe, Leiden, Netherlands
Background/Purpose: Both the IL-12 and IL-23 pathways have been linked to SLE pathogenesis. The anti-IL-12/23 p40 monoclonal antibody ustekinumab (UST), which is approved for psoriasis,…
Abstract Number: 744 • 2015 ACR/ARHP Annual Meeting
Longitudinal Assessment of Th1 and Th2 Cytokines: A Comparison Between Adult-Onset and Childhood-Onset Systemic Lupus Erythematous
Karina Pelicari¹, Mariana Postal¹, Nailu A. Sinicato², Fernando A. Peres¹, Roberto Marini Sr.³, Lilian Tereza Costallat⁴ and Simone Appenzeller⁵, ¹Medicine, State University of Campinas, Campinas, Brazil, ²Pediatrics, State University of Campinas, Campinas, Brazil, ³Pediatric Rheumatology Unit, State University of Campinas, São Paulo, Brazil, ⁴RUA EZEQUIEL MAGALHAES,26, Unicamp, Campinas, Brazil, ⁵Division of Rheumatology, Faculty of Medical Science, State University of Campinas, São Paulo, Brazil
Background/Purpose: The clinical presentation may be different between adult-onset SLE (aSLE) and childhood-onset SLE (cSLE). The profile of cytokine may the clarify of SLE pathophysiology. The…
Abstract Number: 2735 • 2014 ACR/ARHP Annual Meeting
Association of a-Kinase Anchoring Protein-79 (AKAP79) to PKC Mediates Inhibition of IL2 Transcription and Erk Activation in T Cells
Gabriel Criado¹, María J. Pérez-Lorenzo¹, María Galindo², Jose L. Pablos² and Abel Suarez-Fueyo¹, ¹Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain
Background/Purpose A-Kinase anchoring Protein AKAP79 associates to and regulates the activity of PKA, PKC and calcineurin, key regulators of T cell activation. We have previously…
Abstract Number: 2685 • 2014 ACR/ARHP Annual Meeting
Ten-Eleven Translocation 2 Protein Down-Regulates DNA Methylation of Interleukin-17A Promoter and Induces Its Expression in CD4⁺t Cells of Patients with Systemic Lupus Erythematosus
Duo Li, Qian Tang, Lina Tan, Ming Zhao, Gongping Liang, Yang Yang and Qianjin Lu, Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: Recent evidence indicates that IL-17A plays a key role in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE). SLE patients have…
Abstract Number: 634 • 2013 ACR/ARHP Annual Meeting
IL-21/IL-21R Interaction On Lymphocyte Subsets From Lupus Patients
Vinh Nguyen¹, Horea Rus², Cosmin Tegla² and Violeta Rus³, ¹Medicine, University of Maryland School of Medicine, Baltimore, MD, ²Neurology, University of Maryland School of Medicine and Veteran Affairs Medical Center, Baltimore, MD, ³Medicine, University of Maryland School of Medicine and Veteran Affairs Medical Center, Baltimore, MD
Background/Purpose: We have previously shown that IL-21 promotes autoimmunity in a mouse model of lupus through both CD4 and B cell intrinsic mechanisms. Recent studies…
Abstract Number: 740 • 2012 ACR/ARHP Annual Meeting
Select Soluble Inflammatory Mediators Are Detected Prior to and Increase At Systemic Lupus Erythematosus Classification
Melissa E. Munroe¹, Jourdan R. Anderson², Julie M. Robertson³, Timothy B. Niewold⁴, George C. Tsokos⁵, Michael P. Keith⁶, John B. Harley⁷ and Judith A. James⁸, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁵Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA, ⁶Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ⁷Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁸Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation; Oklahoma University Health Sciences Center, Oklahoma City, OK
Background/Purpose: The processes that lead to clinical illness in systemic lupus erythematosus (SLE) years before diagnosis are not well characterized. Several cytokines have been associated…
Abstract Number: 673 • 2012 ACR/ARHP Annual Meeting
Altered Soluble Mediators in Individuals with Incomplete Lupus (ILE) in the Lupus Autoimmunity in Relatives (LAUREL) Study
Melissa E. Munroe¹, Jill M. Norris², Joel M. Guthridge³, Diane L. Kamen⁴, Kathy Moser Sivils⁵, Timothy B. Niewold⁶, Gary S. Gilkeson⁷, Michael H. Weisman⁸, Mariko L. Ishimori⁸, Daniel J. Wallace⁹, David R. Karp¹⁰, John B. Harley¹¹ and Judith A. James¹², ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁷Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ¹¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE is a complex autoimmune disease marked by autoantibody production and immune dysregulation. Identification of at-risk populations is essential to minimize morbidity and mortality…
Abstract Number: 664 • 2012 ACR/ARHP Annual Meeting
Estrogen Upregulates Interleukin-21 Production of Clusters of Differentiation 4 Positive T Lymphocytes in Patients with Systemic Lupus Erythematosus
Jennifer Lee¹, Daejun Kim¹, Jae Ho Lee¹, Seung Min Jung¹, Mi-La Cho², Seung-Ki Kwok¹, Ji Hyeon Ju¹, Kyung-Su Park¹, Sung-Hwan Park¹ and Ho-Youn Kim¹, ¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul, South Korea, ²Rheumatism Research Center, Catholic Research Institute of Medical Science, Rheumatic research center, Catholic University of Korea, Seoul, South Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease in which various organs and tissues are damaged through abnormal immune responses mediated by tissue-binding autoantibodies…
Abstract Number: 645 • 2012 ACR/ARHP Annual Meeting
Altered Soluble Inflammatory Mediators Mark Impending Systemic Lupus Erythematosus Disease Flare in European-American Lupus Patients Who Receive Influenza Vaccination
Melissa E. Munroe¹, Jourdan R. Anderson², Joan T. Merrill³, Joel M. Guthridge⁴, Virginia C. Roberts⁴, Gillian M. Air⁵, Linda F. Thompson⁶ and Judith A. James⁷, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Biochemistry, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Immunobiology and Cancer, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE is a multifaceted autoimmune disease denoted by immune dysregulation that contributes to increased morbidity and mortality in part due to infectious complications. Vaccination…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].